8-K current report · filed Sep 29, 2026

Lexeo Therapeutics, Inc. (LXEO) 8-K Current Report: September 29, 2026

Item 2.01Item 3.02LXEO overview

Short answer

Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.02 (Unregistered Sales of Equity Securities). Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments.

Lexeo Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments
  • Up to $1.0M additional cash contingent on specified events, creating potential future acquisition cost
  • Up to $12.0M milestone payments over 12 years tied to development and regulatory achievements
  • Milestone settlement split between cash and Lexeo shares, creating possible future dilution
  • Milestones are uncertain, with no guaranteed payments or required resource commitment beyond commercially reasonable efforts

Item 3.02 · Unregistered Sales of Equity Securities

  • Common Stock issued in the Merger, creating potential dilution for existing Lexeo shareholders
  • Shares issued without Securities Act registration under Section 4(a)(2) and/or Regulation D exemptions
  • Merger-related contingent consideration may require additional future equity issuance
  • Equity issuance terms and share count are contained in Item 2.01, which investors should review for dilution impact

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lexeo Therapeutics, Inc. 8-K filings

Get the next LXEO 8-K as it lands

Follow LXEO for push alerts, or ask the research agent what this filing means.